Premium
Brentuximab vedotin: A retrospective multicenter analysis of its indication, safety and efficacy in Argentina
Author(s) -
Negri Aranguren M.F.,
Shanley C.,
Cranco S.,
Otero V.,
Fiad L.,
Fernandez I.,
Miodosky M.,
Kusminsky G.,
Corso A.,
Bistmans A.,
Huber M.,
Marull M.,
Jarchum S.,
Guanchiale L.,
Marquez M.,
Beligoy L.,
Cerutti I.,
Navieckas A.,
Tamashiro M.,
Pujol M.,
Taus R.,
Canosa V.,
Lopez Galletti L.,
Prates M.V.,
Riddick M.,
Pavlovsky A.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2439_62
Subject(s) - medicine , brentuximab vedotin , adverse effect , refractory (planetary science) , clinical endpoint , toxicity , retrospective cohort study , surgery , oncology , lymphoma , clinical trial , hodgkin lymphoma , physics , astrobiology